Trial Profile

Monitoring of the immune responses following mogamulizumab containing treatment in patients with adult T-cell leukemia-lymphoma (MIMOGA study)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 23 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mogamulizumab (Primary)
Indications Adult T-cell leukaemia-lymphoma
Focus Pharmacodynamics
Acronyms MIMOGA

Most Recent Events

22 Aug 2022 Planned End Date changed from 31 Jul 2020 to 31 Jul 2027.
01 Feb 2022 Results of an analysis assessed the clinical significance of the immunoglobulin G heavy-chain repertoire in peripheral blood mononuclear cells of adult T-cell leukaemia-lymphoma patients receiving mogamulizumab published in the British Journal of Haematology
24 Apr 2019 Results demonstrating the presence of skin-directed autoantibodies after mogamulizumab treatment published in the Clinical Cancer Research.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com